19:23 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A four-compound cocktail could enhance the efficiency of CRISPR-based editing in pluripotent stem cells. The method involves CRISPR-based editing in pluripotent stem cells with systems based on CRISPR from Prevotella and Francisella 1...
01:44 , Feb 2, 2018 |  BC Innovations  |  Translation in Brief

Ubiquitin choke point

Takeda has shown its first-in-class UBA1 inhibitor could safely treat cancer by blocking a protein on which virtually all cells depend for ubiquitin-mediated protein degradation, upending conventional wisdom about how to disrupt the pathway that...
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
04:24 , Dec 10, 2016 |  BioCentury  |  Product Development

AML advances

Treatment paradigms in most cancers have followed a predictable if sometimes slow progression from chemotherapy, to agents that target features prevalent among a classically defined cancer type, to personalized approaches targeting features specific to an...
07:00 , Oct 13, 2014 |  BioCentury  |  Strategy

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Neuronal precursor cell expressed developmentally downregulated 8 (NEDD8); cullin 4A (CUL4A) Cell culture and human...
07:00 , Mar 25, 2013 |  BioCentury  |  Emerging Company Profile

Cleave: Proteasome alternatives

Cleave Biosciences Inc. is developing small molecules against new targets that regulate protein homeostasis. The compounds could offer better bioavailability than existing proteasome inhibitors and work in a wider range of cancers, including solid tumors. The...
08:00 , Jan 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Neural precursor cell expressed developmentally downregulated 8 (NEDD8); NEDD8 activating enzyme...
07:00 , Sep 20, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation NEDD8 activating enzyme (NAE) Cell culture studies suggest inhibiting neddylation with NAE inhibitors could help treat...